Aptar Pharma Partners with CHI to Introduce Advanced Dry Powder Inhaler for Lung Medication Delivery

Aptar Pharma, a global leader in drug delivery solutions, has announced an exclusive collaboration with Cambridge Healthcare Innovations (CHI) to bring the Quattrii Dry Powder Inhaler (DPI) platform to the market. Under this agreement, Aptar Pharma will be responsible for the commercialization and customer engagement efforts for Quattrii, aiming to streamline its availability to drug developers and ultimately to patients. Aptar will integrate its pharmaceutical services to support the platform’s growth and ensure a smooth path to market readiness.

The Quattrii DPI platform is designed for effective delivery of medium to high doses of powdered medications to the lungs. Its unique mechanism allows the inhaler to selectively filter the active ingredient, leaving larger carrier particles behind in the blister. This feature enhances the effectiveness of inhalation, reducing the risk of coughing and increasing the deposition of the drug in the lungs. The device can also be adjusted to deliver all particles, adding flexibility for different therapeutic needs.

Aptar Pharma brings a robust suite of support services to the partnership. Their offerings include formulation development, device optimization, and patient onboarding support through their affiliated companies like Nanopharm and Noble, as well as Aptar Digital Health’s digital health services. These resources will enable Aptar Pharma to deliver a customized and value-added experience for clients, aimed at improving patient outcomes across a variety of respiratory conditions.

David Harris, CEO of CHI, expressed enthusiasm about the partnership, noting that the Quattrii platform could broaden treatment possibilities by enabling high-dose delivery of low-potency drugs. Both companies are optimistic about the potential of this collaboration to make significant advancements in respiratory drug delivery and improve patient care.